Sector revisions Alnylam Pharmaceuticals, Inc.

Equities

Market Closed - Nasdaq Other stock markets 01:30:00 14/03/2026 am IST			5-day change	1st Jan Change
313.41 ^USD	-1.20%		-2.26%	-21.18%

06/03	Tenaya Therapeutics and Alnylam Pharmaceuticals Enter Research Collaboration Agreement	CI
05/03	Tenaya Therapeutics inks $1.13 billion deal with Alnylam for heart-disease treatments	RE

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	4m. EPS revision	4m. Revenue rev.	1y. EPS revision	1y. Revenue rev.	Visibility	Nbr of analysts
	ALNYLAM PHARMACEUTICALS, INC.							25
	ELI LILLY AND COMPANY							29
	JOHNSON & JOHNSON							24
	ABBVIE INC.							29
	ROCHE HOLDING AG							19
	ASTRAZENECA PLC							21
	NOVARTIS AG							21
	MERCK & CO., INC.							27
	AMGEN INC.							29
	GILEAD SCIENCES, INC.							28
	NOVO NORDISK A/S							22
	PFIZER INC.							26
	BRISTOL-MYERS SQUIBB COMPANY							25
	VERTEX PHARMACEUTICALS INCORPORATED							28
	GSK PLC							20
	SANOFI							23
	CHUGAI PHARMACEUTICAL CO., LTD.							15
	TAKEDA PHARMACEUTICAL COMPANY LIMITED							15
	JIANGSU HENGRUI PHARMACEUTICALS CO.,LTD							17
	HALEON PLC							16
	Average							23
	Weighted average by Cap.							25